Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 6/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25120952 | 0.94 | USP2 (0.43) | USP2LPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL24968559 | 0.89 | LPAR1 (0.40) | USP2LPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL24968554 | 0.89 | LPAR1 (0.40) | USP2LPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL24968569 | 0.88 | LPAR1 (0.39) | USP2LPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL25869522 | 0.88 | LPAR1 (0.39) | USP2LPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL24968266 | 0.88 | LPAR1 (0.39) | USP2LPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL24968570 | 0.88 | LPAR1 (0.39) | USP2LPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL24968270 | 0.87 | LPAR1 (0.38) | USP2LPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL24968566 | 0.87 | LPAR1 (0.38) | USP2LPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL24968269 | 0.83 | MAPT (0.50) | LPAR1LPAR3LPAR2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218399-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SUZHOU ABOGEN BIOSCIENCES CO LTD (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240218399-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SUZHOU ABOGEN BIOSCIENCES CO LTD (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
| WO-2023125889-A1 | QUADRIVALENT MRNA VACCINES FOR INFLUENZA VIRUSES | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023006062-A1 | NUCLEIC ACID VACCINES FOR MUTANT CORONAVIRUS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | USP2 2151/4885LPAR1 191/4885LPAR3 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.